Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
Official title:
A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Efficacy of Indacaterol (300 µg o.d.) Using Salmeterol (50 µg b.i.d.) as an Active Control in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
Verified date | October 2011 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | Japan: Ministry of Health, Labor and Welfare |
Study type | Interventional |
This study is designed to collect long term safety data of indacaterol (300 µg o.d.) in Japanese patients with moderate to severe COPD. Data from this study will be used for the registration of indacaterol in Japan.
Status | Completed |
Enrollment | 186 |
Est. completion date | October 2010 |
Est. primary completion date | October 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: 1. Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines) and: - Smoking history of at least 20 pack-years - Post-bronchodilator FEV1 <80% and =30% of the predicted normal value - Post-bronchodilator FEV1/FVC (forced vital capacity) <70% Exclusion Criteria: 1. Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period 2. Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1 3. Patients with concomitant pulmonary disease 4. Patients with a history of asthma 5. Patients with diabetes Type I or uncontrolled diabetes Type II 6. Any patient with lung cancer or a history of lung cancer 7. Patients with a history of certain cardiovascular comorbid conditions 8. Patients who have been exposed to indacaterol previously. (Except for any patient who enrolled in Study CQAB149B1302) Other protocol-defined inclusion/exclusion criteria may apply |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Japan | Novartis Investigator Site | Asahikawa | |
Japan | Novartis Investigator Site | Bunkyo-ku | |
Japan | Novartis Investigator Site | Gifu | |
Japan | Novartis Investigator Site | Hamamatsu | |
Japan | Novartis Investigator Site | Himeji | |
Japan | Novartis Investigator Site | Hiroshima | |
Japan | Novartis Investigator Site | Iwata | |
Japan | Novartis Investigator Site | Kanazawa | |
Japan | Novartis Investigator Site | Kasaoka | |
Japan | Novartis Investigator Site | Kawasaki | |
Japan | Novartis Investigator Site | Kishiwada | |
Japan | Novartis Investigator Site | Kitakyushu | |
Japan | Novartis Investigator Site | Kochi | |
Japan | Novartis Investigator Site | Koga | |
Japan | Novartis Investigator Site | Kurume | |
Japan | Novartis Investigator Site | Kyoto | |
Japan | Novartis Investigator Site | Maebashi | |
Japan | Novartis Investigator Site | Matsusaka-city | |
Japan | Novartis Investigator Site | Morioka | |
Japan | Novartis Investigator Site | Nagaoka-city | |
Japan | Novartis Investigator Site | Nagoya | |
Japan | Novartis Investigator Site | Naka-gun | |
Japan | Novartis Investigator Site | Noda | |
Japan | Novartis Investigator Site | Obihiro | |
Japan | Novartis Investigator Site | Sakai | |
Japan | Novartis Investigator site | Sapporo | |
Japan | Novartis Investigator Site | Sendai | |
Japan | Novartis Investigator Site | Setagaya-ku | |
Japan | Novartis Investigator Site | Sumida-ku | |
Japan | Novartis Investigator Site | Tenri | |
Japan | Novartis Investigator Site | Tokyo | |
Japan | Novartis Investigator Site | Ube | |
Japan | Novartis Investigator Site | Wakayama | |
Japan | Novartis Investigator Site | Yabu | |
Japan | Novartis Investigator Site | Yanagawa | |
Japan | Novartis Investigator Site | Yokkaichi | |
Japan | Novartis Investigator Site | Yokohama |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Number of Participants With a Clinically Notable Pulse Rate During 52 Weeks of Treatment | The number of participants with newly occurring or worsening clinically notable vital sign: Pulse Rate in beats per minute (bpm) at anytime post baseline (BL) by treatment. Low Pulse Rate was defined as a pulse rate <40 bpm or <= to 50 bpm and a decrease from baseline >= to 15 bpm. High Pulse Rate was defined as a pulse rate >130 bpm or >= to 120 bpm and an increase from baseline >= to 15 bpm. | 52 weeks | Yes |
Primary | The Number of Participants With a Clinically Notable Systolic Blood Pressure During 52 Weeks of Treatment | The number of participants with newly occurring or worsening clinically notable vital sign: Systolic Blood Pressure (mmHg) at anytime post baseline (BL) by treatment. A Low Systolic Blood Pressure was defined as a systolic blood pressure measurement: <75 mmHg or <= to 90 mmHg and a decrease from baseline >= to 20 mmHg. A High Systolic Blood Pressure was defined as a systolic blood pressure measurement: >200 mmHg or >= to 180 mmHg and an increase from baseline >= to 20 mmHg. |
52 weeks | Yes |
Primary | The Number of Participants With a Clinically Notable Diastolic Blood Pressure During 52 Weeks of Treatment | The number of participants with newly occurring or worsening clinically notable vital sign: Diastolic blood pressure (mmHg) at anytime post baseline (BL) by treatment. A Low Diastolic Blood Pressure was defined as a diastolic blood pressure measurement: <40 mmHg or <= to 50 mmHg and a decrease from baseline >= to 15 mmHg. A High Diastolic Blood Pressure was defined as a diastolic blood pressure measurement: >115 mmHg or >= to 105 mmHg and an increase from baseline >= to 15 mmHg. |
52 weeks | Yes |
Primary | The Number of Participants With a Clinically Notable QTc Interval Value During 52 Weeks of Treatment | The number of participants with newly occurring or worsening clinically notable QTc Interval value at anytime post baseline. The QTc interval is calculated using Fridericia's formula: QTc= QT/cube root RR. QTc is the interval between the Q and T waves corrected for heart rate and RR is the interval between two R waves in milliseconds (ms). Notable QTc interval >450 ms for males and >470 ms for females. The maximum QTc increase from baseline at any time during the study was also tabulated with absolute and relative frequencies for categories 30- 60 ms and >60 ms. |
52 weeks | Yes |
Primary | Serum Potassium (mmol/L) at Weeks 4, 8, 12, 24, 36, 44, and 52 | The least squares mean of the serum potassium in mmol/L at weeks 4, 8, 12, 24, 36, 44 and 52. Mixed model used baseline serum potassium as a covariate. | 4, 8, 12, 24, 36, 44, and 52 weeks | Yes |
Primary | Blood Glucose (mmol/L) 1 Hour Post Dose at Weeks 4, 8, 12, 24, 36, 44, and 52 | The least squares mean of the blood glucose in mmol/L at weeks 4, 8, 12, 24, 36, 44 and 52. Mixed model used baseline blood glucose as a covariate. | 4, 8, 12, 24, 36, 44, and 52 weeks | Yes |
Secondary | Trough Forced Expiratory Volume in 1 Second (FEV1) After 12, 24 and 52 Weeks | Trough FEV1 was defined as the mean of the values at 23 h 10 min and 23 h 45 min after dosing at clinic on the previous day. Trough FEV1 was analyzed after 12, 24 and 52 weeks using a mixed model which contained the baseline FEV1 measurement, FEV1 prior to inhalation and FEV1 30 minutes post inhalation of salbutamol as covariates. | After 12, 24 and 52 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Withdrawn |
NCT01377428 -
Efficacy of Indacaterol 150 µg Versus Formoterol
|
Phase 4 |